Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.33 |
| ▸ | CDC25A | P30304 | 10/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748615 | 0.87 | HTR2A (0.39) | CES1ALDH1A1ALDH2ALDH3A1CDC25A | |
| SCHEMBL6749836 | 0.80 | ACHE (0.44) | — | |
| SCHEMBL7674175 | 0.78 | CES1 (0.38) | CES1BCHEALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL6744931 | 0.72 | CYP2D6 (0.48) | ALDH1A1DRD3 | |
| SCHEMBL17298325 | 0.65 | HTR2A (0.44) | CES1BCHEALDH1A1DRD3 | |
| SCHEMBL12659970 | 0.64 | MEN1 (0.46) | CES1BCHEALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL17298327 | 0.64 | PIM1 (0.46) | CES1BCHEALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL28591995 | 0.63 | CES1 (0.81) | CES1BCHEALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL6745540 | 0.63 | CYP2D6 (0.47) | ALDH1A1DRD3 | |
| SCHEMBL24255189 | 0.62 | TTR (0.40) | CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703388-B2 | DIBENZODIAZEPINE DERIVATIVES; ANTIHISTAMINES, LEUKOTRIENE INHIBITORS, ANTIALLERGENS, ANTIASTHMATICS; HAY FEVER, ATOPIC DERMATITIS, AND URTICARIA TREATMENT | EISAI CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| US-6489336-B2 | PHENOTHIAZINE, ACRIDAN, ACRIDONE OXIME, ACRIDONE HYDRAZONE, OR DIBENZODIAZEPINE DERIVATIVES; TYROSINE KINASE INHIBITORS; TREATING ALLERGIC DISEASES | EISAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6333322-B1 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, URTICARIA, HAY FEVER, GASTROINTESTINAL ALLERGY AND FOOD ALLERGY | EISAI CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0889037-A1 | NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | CES1 501/4885BCHE 530/4885ALDH1A1 149/4885 |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | CES1 501/4885BCHE 530/4885ALDH1A1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.